154 related articles for article (PubMed ID: 17904845)
1. Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents.
Patch RJ; Brandt BM; Asgari D; Baindur N; Chadha NK; Georgiadis T; Cheung WS; Petrounia IP; Donatelli RR; Chaikin MA; Player MR
Bioorg Med Chem Lett; 2007 Nov; 17(22):6070-4. PubMed ID: 17904845
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.
Illig CR; Chen J; Wall MJ; Wilson KJ; Ballentine SK; Rudolph MJ; DesJarlais RL; Chen Y; Schubert C; Petrounia I; Crysler CS; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Meegalla SK
Bioorg Med Chem Lett; 2008 Mar; 18(5):1642-8. PubMed ID: 18242992
[TBL] [Abstract][Full Text] [Related]
3. Structure-based optimization of a potent class of arylamide FMS inhibitors.
Meegalla SK; Wall MJ; Chen J; Wilson KJ; Ballentine SK; Desjarlais RL; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Illig CR
Bioorg Med Chem Lett; 2008 Jun; 18(12):3632-7. PubMed ID: 18495479
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors.
Wall MJ; Chen J; Meegalla S; Ballentine SK; Wilson KJ; DesJarlais RL; Schubert C; Chaikin MA; Crysler C; Petrounia IP; Donatelli RR; Yurkow EJ; Boczon L; Mazzulla M; Player MR; Patch RJ; Manthey CL; Molloy C; Tomczuk B; Illig CR
Bioorg Med Chem Lett; 2008 Mar; 18(6):2097-102. PubMed ID: 18289848
[TBL] [Abstract][Full Text] [Related]
5. Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors.
Huang H; Hutta DA; Rinker JM; Hu H; Parsons WH; Schubert C; DesJarlais RL; Crysler CS; Chaikin MA; Donatelli RR; Chen Y; Cheng D; Zhou Z; Yurkow E; Manthey CL; Player MR
J Med Chem; 2009 Feb; 52(4):1081-99. PubMed ID: 19193011
[TBL] [Abstract][Full Text] [Related]
6. Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3.
Patch RJ; Baumann CA; Liu J; Gibbs AC; Ott H; Lattanze J; Player MR
Bioorg Med Chem Lett; 2006 Jun; 16(12):3282-6. PubMed ID: 16580199
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 3',4',5'-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation.
Rao YK; Fang SH; Tzeng YM
Bioorg Med Chem; 2009 Dec; 17(23):7909-14. PubMed ID: 19875299
[TBL] [Abstract][Full Text] [Related]
8. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
9. Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).
Illig CR; Manthey CL; Wall MJ; Meegalla SK; Chen J; Wilson KJ; Ballentine SK; Desjarlais RL; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Donatelli RR; Yurkow E; Zhou Z; Player MR; Tomczuk BE
J Med Chem; 2011 Nov; 54(22):7860-83. PubMed ID: 22039836
[TBL] [Abstract][Full Text] [Related]
10. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
[TBL] [Abstract][Full Text] [Related]
11. Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.
Scott DA; Balliet CL; Cook DJ; Davies AM; Gero TW; Omer CA; Poondru S; Theoclitou ME; Tyurin B; Zinda MJ
Bioorg Med Chem Lett; 2009 Feb; 19(3):697-700. PubMed ID: 19112018
[TBL] [Abstract][Full Text] [Related]
12. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
13. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
16. 3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor.
Scott DA; Dakin LA; Del Valle DJ; Diebold RB; Drew L; Gero TW; Ogoe CA; Omer CA; Repik G; Thakur K; Ye Q; Zheng X
Bioorg Med Chem Lett; 2011 Mar; 21(5):1382-4. PubMed ID: 21295474
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-inflammatory FMS inhibitors.
Huang H; Hutta DA; Hu H; DesJarlais RL; Schubert C; Petrounia IP; Chaikin MA; Manthey CL; Player MR
Bioorg Med Chem Lett; 2008 Apr; 18(7):2355-61. PubMed ID: 18342505
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening to successfully identify novel janus kinase 3 inhibitors: a sequential focused screening approach.
Chen X; Wilson LJ; Malaviya R; Argentieri RL; Yang SM
J Med Chem; 2008 Nov; 51(21):7015-9. PubMed ID: 18844338
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.
Dushin RG; Nittoli T; Ingalls C; Boschelli DH; Cole DC; Wissner A; Lee J; Yang X; Morgan P; Brennan A; Chaudhary D
Bioorg Med Chem Lett; 2009 May; 19(9):2461-3. PubMed ID: 19345579
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of novel anilinoquinolines as c-fms inhibitors.
Smalley TL; Chamberlain SD; Mills WY; Musso DL; Randhawa SA; Ray JA; Samano V; Frick L
Bioorg Med Chem Lett; 2007 Nov; 17(22):6257-60. PubMed ID: 17870531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
